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Abstract
Mucosal candidiasis is frequent in immunocompromised HIV-infected highly active antiretroviral (HAART) naive patients or those who
have failed therapy. Mucosal candidiasis is a marker of progressive immune deﬁciency. Because of the frequently marked and prompt
immune reconstitution induced by HAART, there is no recommendation for primary antifungal prophylaxis of mucosal candidiasis in the
HIV setting in Europe, although it has been evidenced as effective in the pre-HAART era. Fluconazole remains the ﬁrst line of therapy
for both oropharyngeal candidiasis and oesophageal candidiasis and should be preferred to itraconazole oral solution (or capsules when
not available) due to fewer side effects. For patients who still present with ﬂuconazole-refractory mucosal candidiasis, oral treatment
with any other azole should be preferred based on precise Candida species identiﬁcation and susceptibility testing results in addition to
the optimization of HAART when feasible. For vaginal candidiasis, topical therapy is preferred.
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Introduction
Oropharyngeal (OPC) and oesophageal (OEC) candidiasis are
by far the most common fungal infections among patients with
human immunodeﬁciency virus (HIV) infection or acquired
immunodeﬁciency syndrome (AIDS) [1]. This guideline focuses
on patients with HIV infection or AIDS with Candida diseases.
The same grading system for the strength of recommendation
and its documented quality of evidence are used throughout of
this guideline as in the majority of the ESCMID Candida guide-
lines. The explanations and abbreviations used in this docu-
ment are given in Table 1 [85].
Before the era of highly active antiretroviral therapy (HA-
ART), OPC occurred in as many as 90% of patients, at some
point during the course of HIV infection [1]. Although the
incidence of mucosal Candida colonization and infection has
been dramatically reduced with the introduction of HAART,
it remains a common opportunistic infection in those HIV-
infected patients without access to HAART or those in
whom antiviral therapy is started late.
Oesophageal candidiasis was the leading opportunistic
infection before the HAART era [2] and remains the second
AIDS-deﬁning illness in Europe [3]. In addition, mucosal can-
didiasis is still problematic in patients with poor adherence
to treatment and/or multiple virological–immunological fail-
ures. The occurrence of OPC and OEC are indicators of
profound immune suppression, and these syndromes are
most often observed in patients with CD4+ counts
<200 cells/lL with OEC being found in a more advanced
stage of AIDS than OPC [1]. OPC and OEC are more difﬁ-
cult infections to treat in the context of HIV infection com-
pared with other immunocompromised patients [4].
Candida albicans is the most prominent pathogen. This
organism can be found in the oral cavity of up to two-thirds
of healthy individuals [5]. No particular strains have a pre-
ponderance to cause mucosal candidiasis. Acquired ﬂuconaz-
ole (or pan triazole) resistance is related to previous
exposure to ﬂuconazole (or other triazoles), particularly if
repeated and prolonged exposure in the context of profound
immunosuppression [6–8]. Fluconazole resistance is associ-
ated with the cumulative exposure to ﬂuconazole; patients
failing ﬂuconazole have received larger cumulative dosages of
ﬂuconazole (mean value, 8.7 g) [9]. The transmission of iso-
lates (including those resistant to ﬂuconazole) has been doc-
umented between HIV-infected partners [10]. Therefore,
examination of partners is recommended.
In this setting, C. albicans resistance has also been accom-
panied by an emergence of non-albicans Candida species with
intrinsic reduced azole susceptibility in the oral cavity (partic-
ularly C. krusei and C. glabrata [11]) and in the vagina [12].
C. glabrata may cause refractory mucosal candidiasis, particu-
larly in patients with advanced immunosuppression [13].
Candida dubliniensis was ﬁrst associated with OPC in HIV-
infected patients [14]. The introduction of HAART with immu-
nological reconstitution has led to a dramatic decline in the
incidence of refractory disease and of infections caused by
resistant Candida isolates. Barchiesi et al. [11] found that 93%
of Candida collected from oral cavities among 102 HAART-
treated patients remained susceptible to ﬂuconazole, despite
many of these patients receiving repeated courses of triazoles.
Clinical manifestations
Three clinical patterns of OPC have been described: ery-
thematous, pseudo-membranous and angular cheilitis. OPC
can occur at any stage of HIV infection (primary infection,
chronic asymptomatic phase and AIDS), but erythematous
(erythematous patches without white plaques visible on the
anterior or posterior upper palate or diffusely on the ton-
gue) and pseudomembranous (creamy white, plaque-like
lesions of the buccal or oropharyngeal mucosa or tongue
surface) forms are predictive of progressive immunodeﬁ-
ciency [15].
Oesophageal symptoms include retrosternal burning pain,
altered taste and odynophagia. Endoscopic examination
reveals whitish plaques similar to those observed with OPC
that might progress to superﬁcial ulceration of the OEC
mucosa, with central or surface whitish exudates.
As relapse of OPC and OEC is common, it is often associ-
ated with recurrence of intense pain that contributes to
weight loss because of poor nutrition.
TABLE 1. Strength of the ESCMID recommendation and
quality of evidence
Strength of a recommendation
Grade A ESCMID strongly supports a recommendation for use
Grade B ESCMID moderately supports a recommendation for use
Grade C ESCMID marginally supports a recommendation for use
Grade D ESCMID supports a recommendation against use
Quality of evidence
Level I Evidence from at least one properly designed randomized,
controlled trial
Level II* Evidence from at least one well-designed clinical trial,
without randomization; from cohort or case–controlled
analytic studies (preferably from >1 centre); from multiple
time series; or from dramatic results of uncontrolled
experiments
Level III Evidence from opinions of respected authorities, based on
clinical experience, descriptive case studies
*Added index:
r: Meta-analysis or systematic review of randomized control trials.
t: Transferred evidence, that is, results from different patients’ cohorts, or
similar immune-status situation.
h: Comparator group is a historical control.
u: Uncontrolled trial.
a: Published abstract (presented at an international symposium or meeting).
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In contrast, vulvovaginal candidiasis is common among
healthy adult women and is often unrelated to HIV status.
Consequently, recurrent vulvovaginal candidiasis alone can-
not be ascribed to advanced HIV disease.
Candida vulvovaginitis may be mild to moderate in severity
and sporadic (similar to normal hosts). This syndrome is
characterized by a white adherent vaginal discharge that is
associated with burning and itching. In patients with advanced
immunosuppression, episodes may be more severe and more
frequently recurrent. Compared with OPC, vaginal candidia-
sis is frequently more responsive to triazole therapy.
Diagnosis of oropharyngeal candidiasis and
oesophagitis
A diagnosis of OPC is usually made on clinical grounds.
Lesions can be readily scraped with a tongue depressor or
other instrument to obtain samples for a microbiological
diagnosis. Fungal selective media should be used to avoid
overgrowth by colonizing bacteria [16]. Identiﬁcation to spe-
cies level and susceptibility testing are recommended in
recurrent cases of OPC and for patients repeatedly exposed
to ﬂuconazole (and/or other triazoles). If an upper endos-
copy is performed, a biopsy may enable infection to be dis-
tinguished from colonization or other mucosal diseases [16].
The diagnosis of OEC requires endoscopic visualization of
lesions with histopathologic demonstration of characteristic
Candida yeast forms in tissue and culture conﬁrmation of the
presence of Candida species.
The diagnosis of vulvovaginal candidiasis is made with a
combination of characteristic clinical appearances combined
with standard microbiological investigations. The detection of
serum biomarkers such as mannan/antimannan or ß-D-glucan
is not required to conﬁrm a diagnosis of mucosal candidiasis.
Primary prophylaxis of mucosal candidiasis
Despite the demonstrated efﬁcacy of ﬂuconazole, primary
antifungal prophylaxis for the prevention of OPC and OEC is
not recommended in Europe (DI). Fluconazole (200 mg/day)
is superior to clotrimazole troches in a large randomized
multicentric unblinded trial for the prevention of both OEC
and OPC with a greatest beneﬁt in patients with less than
50 CD4/mm3 [17]. In addition, in a double-blind trial, Havlir
et al. [18] observed double the rate of OPC among patients
receiving 400 mg ﬂuconazole weekly compared with those
treated with 200 mg daily. Fluconazole 200 mg/week in a
randomized double-blind placebo-controlled trial involving
HIV-infected women prevented OPC and vaginal candidiasis
but not OEC [19]. In a retrospective study, Manfredi et al.
[20] demonstrated that ﬂuconazole 100 mg/day every
3 weeks prevented the occurrence of OEC vs. no therapy.
Finally, other triazoles such as itraconazole are more effec-
tive than placebo in the prevention of superﬁcial Candida sp.
infections [21] (Table 2).
While OPC may be associated with signiﬁcant morbidity,
the disadvantages of primary prophylaxis include the potential
for drug–drug interactions between triazoles and HAART, the
development of ﬂuconazole resistance and/or cross-resistance
to azoles, the availability of effective antifungal therapy for
OPC and the cost and potential toxicity of triazole antifungal
agents. Thus, the best prophylaxis of both OPC and OEC is
the appropriate compliance to HAART (AII).
Treatment of ﬁrst OPC episodes due to
triazole susceptible isolates
More than 20 years after its introduction, ﬂuconazole
remains the leading antifungal drug that is used for OPC.
Fluconazole is fungistatic against Candida spp. with an oral
bioavailability of over 80%, which is not inﬂuenced by con-
comitant food intake or gastric pH. Penetration into saliva is
excellent. Tablets, oral solution and intravenous formulation
can all be used to treat OPC. Because of hepatic metabolism
via the CYP450 enzyme complex, many drug interactions
with ﬂuconazole have been described. Fluconazole is well
tolerated within the recommended range of doses for muco-
sal candidiasis. Side effects increasingly occur with doses in
excess of 400 mg per day, which are not usually necessary
for treatment of mucosal candidiasis [22]. Finally, EUCAST
and CLSI susceptibility breakpoints have been deﬁned for
ﬂuconazole and C. albicans, C. parapsilosis and C. tropicalis: sus-
ceptible, MIC £2 mg/L; and resistant, MIC >4 mg/L according
to both EUCAST and CLSI (http://www.eucast.org).
Fluconazole at a dosage of 100 mg/day for 7–14 days is
recommended for the ﬁrst-line agent for the treatment of
OPC for adults [23–28] and children (AI) [29,30] (Table 2).
The majority of patients with OPC that is caused by ﬂuco-
nazole-susceptible isolates will respond to therapy within
72 h. Approximately 80% of patients are cured, and a further
10% experience signiﬁcant improvement in their symptoms
[31]. OPC is a mandatory indication of HAART’s initiation
(AII). No long-term suppressive triazole therapy should be
used (DIII).
Potential alternatives to ﬂuconazole include (i) miconazole
as a mucoadhesive tablet 10 or 50 mg once daily for
7–14 days (approved in Europe since 2008 in its 50 mg for-
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mulation) (BI). Miconazole was studied in a randomized trial
vs. ketoconazole (similar efﬁcacy but reportedly had more
episodes of vomiting in patients on ketoconazole) and in a
large phase III double-blind double dummy trial vs. clotrima-
zole (similar efﬁcacy and acceptable tolerability), but not to
the reference drug ﬂuconazole [32–34]; (ii) itraconazole oral
solution. Itraconazole solution for 7–14 days (100 or
200 mg/day) is equivalent to ﬂuconazole for 14 days [35,36]
(BI). Itraconazole solution may be beneﬁcial even without
the attainment of detectable serum levels because of its
direct effect if swished in mouth for few seconds before
swallowing [37]. Itraconazole solution is associated with a
30% increase in itraconazole absorption in comparison with
the capsule formulation [38] and with a comparable rate of
side effects compared with ﬂuconazole [35,36] for OPC.
Itraconazole has a higher incidence of erratic oral bioavail-
ability and drug–drug interactions compared with ﬂuconaz-
ole. The use of itraconazole may be complicated by
cross-resistance to ﬂuconazole. Indeed, in one study, 30% of
ﬂuconazole-resistant isolates were cross-resistant to itraco-
nazole, and itraconazole solution has been shown effective
during OPC in this context against itraconazole susceptible
isolates [39]; (iii) voriconazole has not been studied for
ﬂuconazole-susceptible OPC; (iv) posaconazole (200 mg on
day 1 then 100 mg daily) is also an alternative to ﬂuconazole
[40]. Posaconazole is better tolerated and has fewer interac-
tions compared with both itraconazole and voriconazole, but
has a broad spectrum of activity for treating initial episodes
of OPC and is considered an option for therapy in cases
with ﬂuconazole-resistant Candida sp. (CI).
Topical agents (e.g. amphotericin B lozenges or nystatin)
should not be used for the treatment of OPC because of
suboptimal tolerability (bitter taste, gastro-intestinal side
effects, frequent dosing) and lower efﬁcacy [27] (DI). Fur-
thermore, a recommendation for clotrimazole was not con-
sidered because this agent is not available in Europe. While
clotrimazole is effective, it is less efﬁcacious and associated
with a higher rate of relapses in comparison with ﬂuconazole
at least in some studies [25,26,28]. Finally, acquired
resistance to clotrimazole has been documented in Candida
isolates in OPC [41].
Ketoconazole is efﬁcacious in comparison with ﬂuconazole
and itraconazole but its use is limited by hepatotoxicity,
drug–drug interactions, limited oral bioavailability in the set-
TABLE 2. Recommendations made for patients with HIV infection or AIDS and Candida disease
Intention Intervention SoR QoE Reference/Commentary
Primary prophylaxis of mucosal
candidiasis (OPC/OEC)
Primary antifungal prophylaxis of OPC/OEC D I [17][19][18][20][21] although effective [interactions/
acute therapy effective/induction of resistance/no
mortality related to OPC/cost)
Best prophylaxis is appropriate compliance
to HAART
A II [80][81][82][83][84]
Treatment of ﬁrst episodes of
oropharyngeal candidiasis
(OPC) due to azole
susceptible isolates
HAART should be initiated A II [80][81][82][83][84]
Fluconazole (100 mg/day in adults, at least
7 days)
A I [23][11][26,27][25][28][29][30]
Miconazole mucoadhesive tablet B I [32][33]
Itraconazole oral solution B I [35][36]
Posaconazole (100 mg/day) C I [4]
Voriconazole – – No published data
Topical agents D I [27][29]
Ketoconazole D I [23][11][45][42]
Itraconazole capsules D III Because of poor absorption [39]
Echinocandins and any amphotericin B
formulation
D III No published data
Chronic suppressive therapy D III No published data
Treatment of oesophageal
candidiasis
Start treatment without endoscopy A III In case of oesophageal symptoms and OPC,
endoscopy is not indicated.
Oral ﬂuconazole (200 mg/day for
14–21 days) (or i.v. for those who cannot
swallow)
A I [23][48][46][47]
Itraconazole solution B I [49][46][47]
Echinocandins can be used in patients who
cannot swallow but not better than
Fluconazole
C I [55][56][57][53][54]
Higher relapse rate with caspofungin and
anidulafungin vs ﬂuconazole
Ketoconazole D I [48][42]
Any i.v. amphotericin B formulation D III No role for the management of OEC due to azole
susceptible isolates
Local treatments D III Less effective than ﬂuconazole
Treatment of refractory
OPC/OEC
Itraconazole oral solution (‡200 mg/day) A II [64][63][65]
Posaconazole (400 mg twice daily) A II [66][67]
Voriconazole (200 mg twice daily) C II [68]
Any echinocandin A II [70][71][72]
All echinocandins may be considered equivalent here
Any amphotericin B formulation C III No published data
Suppressive therapy Fluconazole 100–200 mg 3·/week A I [75][76][77][78][19][18][9][79]
HAART, highly active antiretroviral; OEC, oesophageal.
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ting of hypochlorhydria and appears to select for triazole
cross-resistance [11,23,42–45]. Ketoconazole is thus not rec-
ommended for the management of OPC (DI).
Echinocandins should not be considered for OPC episodes
caused by isolates that are susceptible to triazoles due to their
parenteral availability and cost in comparison with ﬂuconazole
(DIII). Finally, any intravenous formulation of amphotericin B is
also not recommended for the management of OPC due to
numerous adverse events and associated nephrotoxicity (DIII).
Treatment of oesophageal candidiasis due
to triazole susceptible isolates
Antifungal therapy for OEC should be initiated without endos-
copy, especially if patients have signs and symptoms of OEC and
oropharyngeal lesions are suggestive of mucosal candidiasis
(AIII). Topical agents are not effective enough and should be
avoided (DIII). Oral ﬂuconazole (200 mg/day for 14–21 days) is
the treatment of choice [46–48] (AI). Intravenous formulation
can be used in case of severe oesophagitis (Table 2).
Itraconazole (oral solution) is an alternative agent that has
been shown to be as effective clinically and mycologically as
ﬂuconazole, but endoscopic cure was found less frequently
especially during short-term therapy in the itraconazole arm
[46,47,49] (BI). Itraconazole capsules are not recommended
because of limited oral bioavailability (DII) The addition of
ﬂucytosine to itraconazole is not superior to ﬂuconazole and
is not recommended [50] (DI).
Voriconazole 200 mg twice daily for 14–21 day is equally
as efﬁcacious as ﬂuconazole, but associated with a higher
incidence of adverse events [51] and more potential drug–
drug interactions, visual abnormalities and phototoxicity in
ambulatory patients (BI).
Oral ﬂucytosine alone was tested against ﬂuconazole but
was proven less effective [52], in addition to potential side
effects (DI). Oral ketoconazole was tested against ﬂuconaz-
ole in a large double-blind trial, and endoscopic and clinical
cure rates were inferior in the ketoconazole arm [48].
Ketoconazole was also tested in a small trial against itrac-
onazole with a higher efﬁcacy than itraconazole [42] (DI).
Finally among azoles, posaconazole has not been speciﬁcally
studied in the context of primary treatment of oesophagitis
in azole susceptible isolates and should be reserved for
refractory or resistant disease.
The echinocandins have been evaluated for the treatment of
AIDS-associated OEC mostly in comparison with ﬂuconazole.
However, these antifungals are only available parenterally
and are much less convenient to use than oral azoles (CI).
Caspofungin is associated with similar response rates and
tolerability compared with ﬂuconazole although higher
relapse rates were observed with caspofungin [53]. Caspo-
fungin has been shown superior (74–91% efﬁcacy) to ampho-
tericin B (63%) in one study [54]. Micafungin (50–150 mg/
day) produces a dose-dependent response rate in OEC [55].
The use of 150 mg/day regimen was comparable both in
terms of efﬁcacy, relapse rate and tolerance compared with
ﬂuconazole (200 mg/day) in a large double-blind study [56].
The currently licensed dosage is 150 mg/day. Similarly, anidu-
lafungin [100 mg/day after loading dose] produces compara-
ble response rates to ﬂuconazole, but the rate of relapse 2
weeks after cessation of therapy was higher [57].
Intravenous formulations of amphotericin play no role for
the management of OEC due to azole susceptible Candida
isolates (DII).
Management of refractory OPC and or
OEC
Refractory OPC or OEC is deﬁned by symptoms that persist
after more than 14 days of ﬂuconazole ‡200 mg/day. This
syndrome is reported in approximately 5% of HIV-infected
patients and typically in those with CD4+ counts <50 cells/
lL who have received multiple and prolonged courses of an-
tifungals/triazole agents for a high number of OPC episodes
[6–8]. The clinical impact of refractory mucosal candidiasis
has been well documented [58]. In this situation, careful
identiﬁcation to species level and in vitro susceptibility testing
to ﬂuconazole and other triazoles are mandatory. Detection
of resistance based on in vitro established breakpoints is
indeed of major importance as mucosal candidiasis is one of
the clinical settings where the correlation between in vitro
results and in vivo outcome has been established [59,60].
Any use of a topical antifungal agent such as amphotericin
B [61] should be avoided because of low efﬁcacy rates (DIII).
The use of ﬂuconazole at a higher daily dosage may be bene-
ﬁcial at least transiently, particularly with the suspension,
which provides increased salivary concentrations [62] (BIII).
Itraconazole solution (up to 600 mg/day) is an alternative
and is associated with a 55–75% response rate, but relapses
occur subsequently [63–65] (AII).
Posaconazole oral suspension [400 mg twice daily (i.e. a
higher dosage than that used for nonrefractory mucosal
infections) for 28–90 days] can also be used and is efﬁcacious
in up to 86% of patients with ﬂuconazole and/or itraconazole
refractory oropharyngeal and/or OEC candidiasis. It has been
approved by EMA in such context. In addition, the use of po-
saconazole is well tolerated up to 90 days of therapy, but
relapses do also occur during the follow-up [66,67] (AII).
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Voriconazole appears to be active against ﬂuconazole-
resistant Candida isolates isolated from mucosal infections
[68] although cross-resistance has also been demonstrated
[69]. Voriconazole has been shown effective in a limited
number of refractory OEC cases [68] (CII). If prolonged
azole therapy is anticipated, periodic monitoring of liver
enzymes should be considered (BIII).
Caspofungin can be used for HIV-infected patients with
clinically ﬂuconazole-refractory OEC or microbiologically
resistant disease. A favourable response is obtained in 83%
and 79% of cases, respectively [70]. Caspofungin can also be
used for patients with refractory OPC/OEC who have expe-
rienced failure or intolerance to polyenes [71] (AII). Anidula-
fungin can also be used in this setting. An open-label clinical
trial also studied anidulafungin in ﬂuconazole-resistant OPC/
OEC in 19 patients with a 95% successful clinical response,
including 11/12 patients with OEC who had endoscopic cure
(92%). Tolerance was acceptable [72] (AII). In addition,
azole-refractory mucosal candidiasis can also be treated with
micafungin 150 mg/day although it has not been speciﬁcally
studied in that setting (AII).
Amphotericin B deoxycholate, amphotericin B lipid com-
plex and liposomal amphotericin B may also be effective in
such setting, but their toxicity proﬁles should receive consid-
erable attention (CII). Preliminary studies have suggested a
potential beneﬁt of adjunctive GM-CSF therapy [73] (CII).
Finally, any perspective of a new HAART regimen appears
crucial in this context [74] (AIII).
Vulvovaginal candidiasis
Vulvovaginal candidiasis usually responds readily to topical
agents (AII). Short-course oral azole therapy although effec-
tive should be avoided (ﬂuconazole (DII), itraconazole oral
solution (DII)). In case of multiple episodes, oral ﬂuconazole
(150 mg/week) should be used to prevent recurrences as
evidenced outside the HIV setting (AI).
Prevention of recurrences
Maintenance therapy or secondary prophylaxis to prevent
recurrences is usually not recommended (DIII). However,
when relapses are frequent and/or severe, long-term oral
triazole use may be considered providing cost and toxicity
are acceptable. Fluconazole maintenance therapy has been
well documented as effective in several randomized studies
performed during the pre-HAART era. It should be
reserved for patients with relapsing OPC/OEC caused by a
ﬂuconazole-susceptible isolate after HAART optimization
(or failing HAART therapy). The range of dosages is large:
50–200 mg/day or 150–400 mg/week] (BI) [9,18,19,75–78]
(Table 2).
Maintenance therapy with ﬂuconazole 100–200 mg 3·/
week should be considered for the case of recurrent infec-
tions to prevent further relapse (AI), but daily administration
of ﬂuconazole should be favoured (BI). A more recent ran-
domized clinical trial has documented that ﬂuconazole
(200 mg three times a week) vs. episodic treatment of recur-
rences therapy was signiﬁcantly associated with fewer cases
of OPC or OEC and fewer invasive fungal infections, but not
with improved survival in HIV patients with CD4+ count
<150 cells/lL. In the latter study, no difference in the rate of
ﬂuconazole-refractory candidiasis was noticed provided that
patients received HAART [79]. Oral posaconazole 400 mg
twice daily can be proposed in case of relapsing OEC due to
ﬂuconazole-resistant Candida isolates (BII). Triazole therapy
is precluded in pregnancy (AIII). Clinical experience, but no
speciﬁc study, suggests that maintenance therapy is not
required in the context of immune reconstitution to CD4-
positive cells >200/lL (AIII).
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